Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 25 Show results per page	View Search Criteria \| Help With Results

Last Modified: 12/4/2006 First Published: 6/1/2001


1.		Phase III Randomized Study of Radiotherapy and Carmustine With or Without O6-Benzylguanine in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				SWOG-S0001 S0001, NCT00017147

Last Modified: 10/18/2007 First Published: 3/1/1999


2.		Phase II Study of O6-benzylguanine in Patients with Surgically Resectable Solid Tumors (Summary Last Modified 02/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				Not specified				NCI				UCCRC-9523 NCI-T98-0038, NCT00003766, T98-0038

Last Modified: 11/16/2006 First Published: 10/1/1999


3.		Phase II Study of O6-Benzylguanine Combined With Carmustine in Patients With Previously Untreated or Refractory Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				Not specified				NCI				CWRU-1A96 NCI-T97-0021, NCT00004072, T97-0021

Last Modified: 11/5/2004 First Published: 4/1/2000


4.		Phase II Study of O6-Benzylguanine and Carmustine in Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				UCCRC-10227 UCCRC-T99-0088, NCI-T99-0088, NCT00005066

Last Modified: 5/1/2001 First Published: 4/1/2000


5.		Phase II Study of Carmustine and O6-Benzylguanine in Patients With Recurrent or Progressive Malignant Anaplastic Gliomas (Summary Last Modified 05/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				DUMC-0059-00-1 DUMC-T98-0059, NCI-T98-0059, NCT00005081, T98-0059

Last Modified: 3/28/2006 First Published: 7/1/2000


6.		Phase II Study of O6-Benzylguanine and Carmustine in Patients With Unresectable Locally Recurrent or Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				UCCRC-10325 CWRU-1699, NCI-T99-0111, NCT00005961, T99-0111

Last Modified: 11/18/2003 First Published: 7/1/2000


7.		Phase II Study of O6-Benzylguanine and Carmustine in Patients With Metastatic Colorectal Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				CWRU-1298 NCI-89, NCT00005981, 89

Last Modified: 11/1/2002 First Published: 10/1/2002


8.		Phase II Study of Carmustine and O6-Benzylguanine in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme Not Requiring Immediate Radiotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				DUMC-3318-01-12 NCI-5632, NCT00046878, 3318-01-12

Last Modified: 2/15/2008 First Published: 12/22/2005


9.		Phase II Study of O6-Benzylguanine and Temozolomide in Pediatric Patients With Recurrent or Progressive High-Grade Gliomas or Brain Stem Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				21 and under				NCI				PBTC-015 PBTC-015, NCI-06-C-0089, NCI-P6692, NCT00275002

Last Modified: 6/20/2008 First Published: 8/6/2006


10.		Phase II Study of Polifeprosan 20 With Carmustine Implant (Gliadel Wafer®) and O6-Benzylguanine in Patients With Recurrent Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				DUMC-5515-06-1R2 DUMC-5515-04-1R0, GP-DUMC-5515-06-1R2, NCT00362921

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute